Medexus Pharmaceuticals Inc.
MDP.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -383.73% | -89.09% | -386.36% | -73.63% | -172.57% |
| Total Depreciation and Amortization | 0.82% | 38.04% | 54.06% | 72.06% | 68.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,516.81% | -49.44% | -58.21% | -83.74% | -121.69% |
| Change in Net Operating Assets | 29.89% | 197.30% | -118.76% | -75.67% | 137.61% |
| Cash from Operations | 66.39% | 16.71% | -51.32% | -52.17% | 41.63% |
| Capital Expenditure | 94.34% | 68.85% | 81.08% | -290.63% | -2,550.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 76.22% | -8.53% | -270.34% | 17.08% | -528.13% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -11,527.91% | -- | -- | 100.00% |
| Cash from Investing | -286.86% | -1,032.78% | 44.50% | -390.78% | -283.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 6.76% | -541.35% | 72.19% | -362.99% | -24.56% |
| Issuance of Common Stock | -97.44% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 51.22% | 53.18% | 64.72% | 34.95% | 38.42% |
| Cash from Financing | -127.52% | 170.43% | 70.47% | -262.42% | 482.98% |
| Foreign Exchange rate Adjustments | -155.56% | 115.56% | -156.67% | 427.27% | 328.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -154.42% | 281.06% | 103.31% | -557.67% | 625.08% |